Is EARS or RYLD a better dividend investment in 2026?

EARS currently yields 65.68% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: EARS offers higher current income.

What is the dividend yield difference between EARS and RYLD?

EARS has a forward dividend yield of 65.68% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 53.29 percentage points.

Home › Compare › EARS vs RYLD

EARS vs RYLD: Dividend Comparison 2026

EARS yields 65.68% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EARS wins by $812.2K in total portfolio value

INVESTMENT

TIME HORIZON10 years

EARS

● Live price

65.68%

Share price

$3.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$857.5K

Annual income

$214,640.91

Full EARS calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — EARS vs RYLD

📍 EARS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EARS	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EARS + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EARS pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS

Annual income on $10K today (after 15% tax)

$5,582.92/yr

After 10yr DRIP, annual income (after tax)

$182,444.77/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, EARS beats the other by $180,164.24/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + RYLD for your $10,000?

EARS: 50%RYLD: 50%

100% RYLD50/50100% EARS

Portfolio after 10yr

$451.4K

Annual income

$108,661.94/yr

Blended yield

24.07%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys

RYLD buys

No recent congressional trades found for EARS or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEARSRYLD

Forward yield	65.68% ✓	12.39%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$857.5K ✓	$45.3K
Annual income after 10y	$214,640.91 ✓	$2,682.98
Total dividends collected	$722.8K ✓	$19.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: EARS vs RYLD ($10,000, DRIP)

Year	EARS Portfolio	EARS Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$17,268	$6,568.14	$11,939	$1,239.34	+$5.3K → EARS
2	$29,077	$10,599.97	$14,158	$1,382.89	+$14.9K → EARS
3	$47,793	$16,681.04	$16,682	$1,532.59	+$31.1K → EARS
4	$76,764	$25,624.68	$19,537	$1,687.64	+$57.2K → EARS
5	$120,602	$38,464.70	$22,752	$1,847.20	+$97.8K → EARS
6	$185,521	$56,477.71	$26,355	$2,010.43	+$159.2K → EARS
7	$279,704	$81,195.93	$30,376	$2,176.45	+$249.3K → EARS
8	$413,691	$114,407.58	$34,847	$2,344.43	+$378.8K → EARS
9	$600,792	$158,142.40	$39,800	$2,513.54	+$561.0K → EARS
10	$857,488	$214,640.91	$45,269	$2,682.98	+$812.2K → EARS

EARS vs RYLD: Complete Analysis 2026

EARS — Stock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this EARS vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHD EARS vs JEPI EARS vs O EARS vs KO EARS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.